Our diverse portfolio of products and product candidates spans a wide range of therapeutic indications and dosage forms. With a special focus on cardiovascular products, we endeavour to improve hospital care for patients who have critical cardiovascular indications. We also further develop and improve already-approved pharmaceuticals and established products, creating new and different solutions.

Product pipeline


Phase 1/2

Phase 3



Sotalol – Arrhythmia disorders
Maxigesic IV ® – Pain Management
HY-EMP-016 – Skin infection disease
HY-REF-039 – Inherited bleeding disorders
HY-EMP-076 – Fusidic acid cream
HY-REF-004 ® – Dental indication
HY-REF-038 ® – Hormone Therapy
HY-REF-029 ® – Infectious Diseases
HY-REF-030 ® – Neurology
HY-CVS-032 – Congestive Heart Failure
HY-CVS-033 – Atrial Fibrillation
HY-CVS-073 – Coronary Heart Disease
HY-CVS-074 – Congestive Heart Disease
HY-CVS-075 – Coronary Heart Disease
Product portfolio

Disclaimer: Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory
requirements/clarifications, including complementary /additional studies

Any questions? Please contact us for all the answers you need!

If you have any enquiries about Hyloris, our mission, activities or any aspect of our company,
please click the link below to get in touch.

Contact Us